Design of new disubstituted imidazo[1, 2-b]pyridazine derivatives as selective Haspin inhibitors. Synthesis, binding mode and anticancer biological evaluation. (1st January 2020)

• Record Type: Journal Article
• Authors: Elie, Jonathan; Feizbakhsh, Omid; Desban, Nathalie; Josselin, Béatrice; Baratte, Blandine; Bescond, Amandine; Duez, Julien; Fant, Xavier; Bach, Stéphane; Marie, Dominique; Place, Matthieu; Ben Salah, Sami; Chartier, Agnes; Berteina-Raboin, Sabine; Chaikuad, Apirat; Knapp, Stefan; Carles, Fabrice; Bonnet, Pascal; Buron, Frédéric; Routier, Sylvain; Ruchaud, Sandrine
• Is Part Of: Journal of enzyme inhibition and medicinal chemistry. Volume 35:Number 1(2020)
• Page Start: 1840
• Page End: 1853
• Publication Date: 2020-01-01
• Subjects: Imidazopyridazine -- Haspin kinase -- co-crystallisation and docking -- cellular effects -- 3D spheroids; Enzyme inhibitors -- Periodicals; Enzyme Inhibitors -- periodicals; Biochemistry -- periodicals; 572.7
• DOI: 10.1080/14756366.2020.1825408
• Languages: English
• ISSNs: 1475-6366

Abstract

Abstract: Haspin is a mitotic protein kinase required for proper cell division by modulating Aurora B kinase localisation and activity as well as histone phosphorylation. Here a series of imidazopyridazines based on the CHR-6494 and Structure Activity Relationship was established. An assessment of the inhibitory activity of the lead structures on human Haspin and several other protein kinases is presented. The lead structure was rapidly optimised using a combination of crystal structures and effective docking models, with the best inhibitors exhibiting potent inhibitory activity on Haspin with IC50 between 6 and 100 nM in vitro . The developed inhibitors displayed anti-proliferative properties against various human cancer cell lines in 2D and spheroid cultures and significantly inhibited the migration ability of osteosarcoma U-2 OS cells. Notably, we show that our lead compounds are powerful Haspin inhibitors in human cells, and did not block G2/M cell cycle transition due to improved selectivity against CDK1/CyclinB. Graphical Abstract: UF0001